Is there a reliable method to assess the complete pathologic response on the tumor after neo-adjuvant chemotherapy in inflammatory breast cancer toward recommendations for the pathologic process? experience in 56 patients treated in a single institution

Breast Journal

Volumn 16, Issue 5, 2010, Pages 464-471

  Mailliez, Audrey ^a   Baranzelli, Marie Christine ^a   Giard, Sylvia ^a   Ceugnart, Luc ^a   Vanlemmens, Laurence ^a   Belkacemi, Yazid ^a   Robin, Yves Marie ^a   Bonneterre, Jacques ^a,b  

^a CENTRE OSCAR LAMBRET   (France)

^b UNIV LILLE   (France)

Author keywords

Clinico pathologic correlation; Inflammatory breast cancer (IBC); Pathologic classifications; Pathologic response; Response assessment

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATORY BREAST CANCER; MASTECTOMY; OVERALL SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

EID: 77956798215     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2010.00957.x     Document Type: Article

References (24)

1. Bell C. A System of Operative Surgery Founded on the Basis of Anatomy. Hartford, CT: Hale and Hosmer, 1816.
2. Haagensen CD. Inflammatory Carcinoma, Diseases of the Breast. Philadelphia PA: W.B. Saunders, 1956: 488-498
3. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991;19:403-410
4. Chevallier B, Bastit P, Graic Y, et al. The Centre H. Becquerel studies in inflammatory non-metastatic breast cancer. Combined modality approach in 178 patients. Br J Cancer 1993;67:594-601.
5. Sataloff DM, Mason BA, Prestipino AJ, et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: A determinant of outcome. J Am Coll Surg 1995;180:297-306.
6. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006;24:2019-2027
7. Panades M, Olivotto IA, Speers CH, et al. Evolving treatment strategies for inflammatory breast cancer: A population-based survival analysis. J Clin Oncol 2005;23:1941-1950
8. Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, et al. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer 2006;106:1000-1006
9. Giordano SH, Hortobagyi GN. Inflammatory breast cancer: Clinical progress and the main problems that must be addressed. Breast Cancer Res 2003;5:284-288
10. Dawood S, Broglio K, Gong Y, et al. Inflammatory Breast Cancer Research Group. Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer 2008;112:1905-11
11. Veyret C, Levy C, Chollet P, et al. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: Ten-year results from the French Adjuvant Study Group GETIS 02 Trial. Cancer 2006;107:2535-2544
12. Cristofanilli M, Valero V, Buzdar AU, et al. Inflammatory breast cancer (IBC) and patterns of recurrence: Understanding the biology of a unique disease. Cancer 2007;110:1436-1444
13. Gonzalez-Angulo AM, Hennessy BT, Broglio K, et al. Trends for inflammatory breast cancer: Is survival improving? Oncologist 2007;12:904-912
14. Chevallier B, Roche H, Olivier JP, et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histological response rate. Am J Clin Oncol 1993;16:223-228
15. Kuroi K, Toi M, Tsuda H, et al. Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer. Breast Cancer 2006;13:38-48.
16. Sinn HP, Schmid H, Junkermann H, et al. Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy. Geburtshilfe Frauenheilkd 1994;54:552-558
17. Honkoop AH, van Diest PJ, de Jong JS, et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998; 77:621-626
18. Smith IC, Miller ID. Issues involved in research into the neoadjuvant treatment of breast cancer. Anticancer Drugs 2001;12(Suppl 1):S25-9.
19. Kaufmann M, von Minckwitz G, Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: Review and recommendations. J Clin Oncol 2003;21:2608
20. Review. Erratum in: J Clin Oncol 2003;21(23): 4469.
21. Amat S, Bougnoux P, Penault-Llorca F, et al. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer 2003;88:1339-1345
22. Low JA, Berman AW, Steinberg SM, et al. Long-term follow- up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol 2004;22:4067-4074
23. Matsuo K, Fukutomi T, Watanabe T, et al. Concordance in pathological response to neoadjuvant chemotherapy between invasive and non-invasive components of primary breast carcinomas. Breast Cancer 2002;9:75-81.
24. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumour and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-469